EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CD105 in the progression and therapy of renal cell carcinoma

Mariam Oladejo, Hong-My Nguyen, Laurence Wood

Cancer Letters · 2023-08 · 570 · 216327

DOI: 10.1016/j.canlet.2023.216327 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-08. Verfasst von Mariam Oladejo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, 796…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular biomarkers that interact with the vascular and immune compartments play an important role in the progression of solid malignancies. CD105, which is a component of the transforming growth factor beta (TGF β) signaling cascade, has long been studied for its role in potentiating angiogenesis in numerous cancers. In renal cell carcinoma (RCC), the role of CD105 is more complicated due to its diverse expression profile on the tumor cells, tumor vasculature, and the components of the immune system. Since its discovery, its angiogenic role has overshadowed other potential functions, especially in cancers. In this review, we aim to summarize the recent evidence and findings of the multifunctional roles of CD105 in angiogenesis and immunomodulation in the context of the various subtypes of RCC, with a specific emphasis on the clear cell RCC subtype. Since CD105 is an established biomarker and tumor antigen, we also provide an update on the preclinical and clinical applications of CD105 as a therapeutic platform in RCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansEndoglinTransforming Growth Factor betaNeovascularization, Pathologic

Stichwörter der Autor:innen

CD105Cancer stem cellsEndoglinRenal cell carcinomaTargeted therapyTumor endothelial cellsTumor vasculature

Substanzen

EndoglinTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, 79601, USA.
  • Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, 79601, USA. Electronic address: Laurence.wood@ttuhsc.edu.

Förderung

  • NCI NIH HHS
  • NIH

Zitieren

APA

Oladejo, M., Nguyen, H. M., & Wood, L. (2023). CD105 in the progression and therapy of renal cell carcinoma. Cancer Letters, 570, 216327. https://doi.org/10.1016/j.canlet.2023.216327

Vancouver

Oladejo M, Nguyen HM, Wood L. CD105 in the progression and therapy of renal cell carcinoma. Cancer Letters. 2023;570:216327. doi:10.1016/j.canlet.2023.216327

BibTeX
@article{Oladejo2023,
  author = {Oladejo, Mariam and Nguyen, Hong-My and Wood, Laurence},
  title = {CD105 in the progression and therapy of renal cell carcinoma},
  journal = {Cancer Letters},
  year = {2023},
  volume = {570},
  pages = {216327},
  doi = {10.1016/j.canlet.2023.216327}
}
Kostenlos starten →